ID   BT145
AC   CVCL_IP10
SY   BT-145; BT 145; CPDM_1279X
DR   BTO; BTO_0005950
DR   PharmacoDB; BT145_116_2019
DR   Wikidata; Q54798421
RX   PubMed=24440720;
RX   PubMed=25184684;
RX   PubMed=25366336;
RX   PubMed=27723727;
RX   PubMed=34610309;
WW   Provider; CPDM; CPDM_1279X; https://docs.google.com/spreadsheets/d/1sxAPF3p6xK2h01zaiQ1ExCWwzhxeZ-oDLN3s3LeJq98/edit?usp=sharing
CC   Part of: Center for Patient Derived Models (CPDM) at Dana-Farber Cancer Institute cell line panel.
CC   Population: Caucasian.
CC   Characteristics: Low-passage-number culture.
CC   Characteristics: Can grow as a neurosphere (PubMed=34610309).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing; Low read coverage.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Brain, right parietal lobe; UBERON=UBERON_0002802.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   87Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 10-04-25; Version: 10
//
RX   PubMed=24440720; DOI=10.1016/j.celrep.2013.12.032; PMCID=PMC4041390;
RA   Chudnovsky Y., Kim D., Zheng S.-Y., Whyte W.A., Bansal M., Bray M.-A.,
RA   Gopal S., Theisen M.A., Bilodeau S., Thiru P., Muffat J., Yilmaz O.H.,
RA   Mitalipova M., Woolard K.D., Lee J., Nishimura R., Sakata N., Fine H.A.,
RA   Carpenter A.E., Silver S.J., Verhaak R.G.W., Califano A., Young R.A.,
RA   Ligon K.L., Mellinghoff I.K., Root D.E., Sabatini D.M., Hahn W.C.,
RA   Chheda M.G.;
RT   "ZFHX4 interacts with the NuRD core member CHD4 and regulates the
RT   glioblastoma tumor-initiating cell state.";
RL   Cell Rep. 6:313-324(2014).
//
RX   PubMed=25184684; DOI=10.1371/journal.pone.0106694; PMCID=PMC4153667;
RA   Holmberg Olausson K., Maire C.L., Haidar S., Ling J., Learner E.,
RA   Nister M., Ligon K.L.;
RT   "Prominin-1 (CD133) defines both stem and non-stem cell populations in
RT   CNS development and gliomas.";
RL   PLoS ONE 9:e106694.1-e106694.11(2014).
//
RX   PubMed=25366336; DOI=10.1093/neuonc/nou303; PMCID=PMC4482855;
RA   Green A.L., Ramkissoon S.H., McCauley D., Jones K., Perry J.A.,
RA   Hsu J.H.-R., Ramkissoon L.A., Maire C.L., Hubbell-Engler B., Knoff D.S.,
RA   Shacham S., Ligon K.L., Kung A.L.-J.;
RT   "Preclinical antitumor efficacy of selective exportin 1 inhibitors in
RT   glioblastoma.";
RL   Neuro-oncol. 17:697-707(2015).
//
RX   PubMed=27723727; DOI=10.1038/nbt.3697; PMCID=PMC5142231;
RA   Stevens M.M., Maire C.L., Chou N., Murakami M.A., Knoff D.S.,
RA   Kikuchi Y., Kimmerling R.J., Liu H.-Y., Haidar S., Calistri N.L.,
RA   Cermak N., Olcum S., Cordero N.A., Idbaih A., Wen P.Y.-C.,
RA   Weinstock D.M., Ligon K.L., Manalis S.R.;
RT   "Drug sensitivity of single cancer cells is predicted by changes in
RT   mass accumulation rate.";
RL   Nat. Biotechnol. 34:1161-1167(2016).
//
RX   PubMed=34610309; DOI=10.1016/j.celrep.2021.109788;
RA   Stockslager M.A., Malinowski S., Touat M., Yoon J.C., Geduldig J.,
RA   Mirza M., Kim A.S., Wen P.Y.-C., Chow K.-H., Ligon K.L., Manalis S.R.;
RT   "Functional drug susceptibility testing using single-cell mass
RT   predicts treatment outcome in patient-derived cancer neurosphere
RT   models.";
RL   Cell Rep. 37:109788.1-109788.12(2021).
//